before and I saw no reason to start now. When data moved from autorads to fluorescent sequencers in the early 90's, labs could produce a lot more data and we added a lot of functionality to Sequencher. Our clients who were already paying for support got those improvements as part of our regular service. I don't see why this is any different."
"We were overwhelmed with the response," said Catherine Murray, Gene Codes Marketing Manager. "Gene Codes' NGS software plans were part of the presentation when our president gave the opening keynote address at ABRF in Salt Lake City a few years ago. It's also been on our web site for months and we've sent out thousands of mailings, so we expected this not to surprise anyone." Asked what was brought up most by conference goers, Murray said, "It wasn't just seeing the speed of some of the algorithms being developed in the community. Attendees were excited about how we had integrated those algorithms into the Sequencher user experience. It's the feeling of using a familiar tool in a much more powerful way."
About Gene Codes Gene Codes Corporation (www.genecodes.com) is an international software firm specializing in bioinformatics software for DNA sequence analysis. Gene Codes' scientist-friendly software tools hold the dominant share in the DNA sequencing sector and are unrivaled in forensic DNA identification for mass fatalities.
Gene Codes' success is built on customer-driven product development, combining the latest programming techniques, rigorous quality control and an open dialogue with customers to produce products of the utmost usability and industry relevance.
As the popularity of Sequencher has grown, so has the company. Gene Codes is a motivated, enthusiastic, high-energy organization based in Ann Arbor, with offices in New York City and in Brighton, England. Gene Codes' corporate culture values flexible collaboration, shared responsibility, an
Page: 1 2 3 Related biology technology :1
|SOURCE Gene Codes Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Scientists from Toronto and Helsinki discover genetic abnormalities after creation of stem cells2
. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch3
. New treatment for rabies advances after successful phase 1 trial in India4
. Lubricating the knee cartilage after ACL injury may prevent osteoarthritis5
. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 6
. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets7
. Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation!8
. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets9
. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose10
. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration11
. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration